Enzyvant Adds Compass’s Jeb Ledell as Its Chief Operating Officer

Xconomy Boston — 

Enzyvant, a Cambridge, MA-based rare disease drug developer, has appointed Jeb Ledell as its chief operating officer. Ledell previously held COO roles at Cambridge-based Compass Therapeutics and at Horizon Discovery Group, a genomics company in the UK. Enzyvant’s lead candidate, RVT-802, a regenerative treatment for pediatric congenital athymia, is expected to receive an FDA decision in December.